Checkpoint Therapeutics (CKPT) Expected to Announce Earnings on Friday

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Friday, May 9th. Analysts expect Checkpoint Therapeutics to post earnings of ($0.10) per share for the quarter.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.47). The company had revenue of $0.04 million during the quarter.

Checkpoint Therapeutics Stock Performance

Shares of CKPT opened at $4.12 on Friday. The stock has a fifty day moving average of $3.78 and a two-hundred day moving average of $3.55. The company has a market capitalization of $345.11 million, a PE ratio of -2.24 and a beta of 1.21. Checkpoint Therapeutics has a fifty-two week low of $1.39 and a fifty-two week high of $4.50.

Insider Transactions at Checkpoint Therapeutics

In other news, CFO William Garrett Gray sold 74,110 shares of the company's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $3.67, for a total value of $271,983.70. Following the completion of the sale, the chief financial officer now owns 1,458,644 shares of the company's stock, valued at $5,353,223.48. This represents a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James F. Oliviero III sold 10,331 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $3.15, for a total value of $32,542.65. Following the sale, the chief executive officer now owns 3,775,019 shares in the company, valued at approximately $11,891,309.85. The trade was a 0.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 121,086 shares of company stock worth $446,879. 2.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Lake Street Capital reiterated a "hold" rating and issued a $4.10 price target (down from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. D. Boral Capital reiterated a "buy" rating and issued a $4.80 price target on shares of Checkpoint Therapeutics in a report on Monday, March 31st. Finally, HC Wainwright reiterated a "neutral" rating and issued a $4.10 price target on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.